Monopar Therapeutics Inc. (MNPR), Thursday announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 trial, confirming the compound's tumor-targeting ability in humans.The study showcased that MNPR-101, a humanized monoclonal antibody, targets cancers expressing the urokinase plasminogen activator receptor such as breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers.Moreover, the biotechnology company has received a clearance in Australia to commence an MNPR-101-Lu Phase 1 therapeutic clinical trial, which is set to launch in the fourth quarter.Currently, Monopar's stock is surging 65.38 percent, to $3.98 over the previous close of $2.40 on the Nasdaq.

Monopar Therapeutics Inc.（MNPR）周四宣布了其正在进行的开放标签MNPR-101-Zr 1期临床试验的积极早期数据，证实了该化合物在人类中的肿瘤靶向能力。该研究表明，人源化单克隆抗体MNPR-101靶向表达尿激酶纤溶酶原激活物受体的癌症，如乳腺癌，结直肠癌，膀胱癌，卵巢癌，胃癌和胰腺癌。此外，该生物技术公司已在澳大利亚获得许可，开始MNPR-101-Lu第一阶段治疗性临床试验，该试验将于第四季度启动。目前，Monopar的股价飙升65.38%，至3.98美元，而此前纳斯达克收盘价为2.40美元。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Get Access to Premium Stock Alerts with RTT Intelligent Investor.

使用RTT Intelligent Investor访问溢价股票警报。

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股